

Pedro Isaacsson Velho

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3888412/publications.pdf>

Version: 2024-02-01

30
papers

1,111
citations

516710

16
h-index

501196

28
g-index

31
all docs

31
docs citations

31
times ranked

1713
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>CDK12</i> -Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. <i>JCO Precision Oncology</i> , 2020, 4, 370-381.	3.0	138
2	Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations. <i>European Urology</i> , 2019, 75, 378-382.	1.9	137
3	Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA repair gene mutations in prostate cancer. <i>Prostate</i> , 2018, 78, 401-407.	2.3	105
4	PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 475-486.	3.1	83
5	Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects. <i>European Urology</i> , 2019, 76, 170-176.	1.9	71
6	Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. <i>Cancer</i> , 2020, 126, 1208-1216.	4.1	70
7	Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. <i>European Urology</i> , 2020, 78, 652-656.	1.9	64
8	The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. <i>European Urology</i> , 2021, 80, 632-640.	1.9	61
9	Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer. <i>European Urology Oncology</i> , 2021, 4, 447-455.	5.4	52
10	Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer. <i>European Urology</i> , 2020, 77, 14-21.	1.9	51
11	Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2020, 136, 16-24.	2.8	41
12	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. <i>European Urology Oncology</i> , 2021, 4, 464-472.	5.4	39
13	Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer. <i>Oncologist</i> , 2021, 26, e270-e278.	3.7	33
14	Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. <i>Journal of Urology</i> , 2020, 204, 63-70.	0.4	32
15	Genomic and clinical characterization of pulmonary-only metastatic prostate cancer: A unique molecular subtype. <i>Prostate</i> , 2019, 79, 1572-1579.	2.3	23
16	Clinical and genomic features of <i>SPOP</i> mutant prostate cancer. <i>Prostate</i> , 2022, 82, 260-268.	2.3	20
17	A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer. <i>Prostate</i> , 2019, 79, 1597-1603.	2.3	18
18	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. <i>BJU International</i> , 2021, 128, 196-205.	2.5	18

#	ARTICLE	IF	CITATIONS
19	Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical Prostatectomy. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	3.0	12
20	Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer. <i>Prostate</i> , 2021, 81, 572-579.	2.3	9
21	Prognostic Value of Systemic Inflammatory Biomarkers in Patients with Metastatic Renal Cell Carcinoma. <i>Pathology and Oncology Research</i> , 2020, 26, 2489-2497.	1.9	6
22	Detection of Early Progression with ¹⁸ F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1270-1273.	5.0	6
23	Investigational therapies targeting the androgen signaling axis and the androgen receptor and in prostate cancer – recent developments and future directions. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 811-822.	4.1	5
24	The development of apalutamide for the treatment of prostate cancer. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 217-226.	5.0	5
25	New approaches to targeting the androgen receptor pathway in prostate cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19, 228-240.	0.3	4
26	Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 165-175.	1.9	4
27	Extreme Responses to a Combination of DNA-Damaging Therapy and Immunotherapy in CDK12-Altered Metastatic Castration-Resistant Prostate Cancer: A Potential Therapeutic Vulnerability. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 183-188.	1.9	3
28	Genomic analysis and clinical outcomes of Primary Gleason Pattern 5 (PG5) prostate cancer (PCa) treated with radical prostatectomy (RP).. <i>Journal of Clinical Oncology</i> , 2019, 37, 54-54.	1.6	0
29	WNT activating pathway mutations confer resistance to first-line antiandrogen therapy in castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 5068-5068.	1.6	0
30	Impact of somatic SPOP (Speckle-Type POZ protein) mutation (mtSPOP) on response to systemic therapy and survival outcome in men with de novo metastatic castration-sensitive prostate cancer (d-mCSPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 329-329.	1.6	0